SKP2, S-phase kinase associated protein 2, 6502

N. diseases: 204; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Our study thus demonstrated that pharmacological inactivation of E2F-1-SKP2-p27 axis is a promising target for restricting cancer progression. 31357480 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Together, this study uncovering Skp2-mediated Twist stabilization and oncogenic functions in CRPC offers new knowledge on how CRPC progresses and acquires chemoresistance during tumor progression. 28346424 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Our results not only reveal the molecular mechanism by which mechanical cues induce Skp2 transcription, but also uncover a role for YAP-Skp2 oncogenic signaling in the relationship between tissue rigidity and cancer progression. 28673931 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE In conclusion, our results revealed hitherto unexplored p27 independent molecular mechanisms for skp2 driven tumor progression. 27684411 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE S‑phase kinase‑associated protein 2 (Skp2) is a novel oncogene, which has been identified to be important in tumor progression and metastasis. 27572672 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. 26497688 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE The F-box protein Skp2, a component of the SCF (Skp1-Cullin 1-F-box) E3 ubiquitin-ligase complex, has been shown to regulate cellular proliferation, cancer progression and metastasis by targeting several cell cycle regulators for ubiquitination and subsequent 26S proteasome degradation. 26114183 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 Biomarker phenotype BEFREE Our study thus provides pharmacological evidence that Skp2 is a promising target for restricting cancer stem cell and cancer progression. 23911321 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. 22322669 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE These data demonstrate that S-phase kinase-associated protein 2 expression is closely linked to tumor progression and represents an independent predictor of poor prognosis in hepatocellular carcinoma. 22204716 2012
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.100 AlteredExpression phenotype BEFREE The expression of SKP2, p27 and phospho-MAPK/ERK1/2 were strongly associated with cervical neoplastic progression (P<0.0001, P=0.006, P=0.003, respectively; Fisher's Exact Test). 17079005 2007